Artificial intelligence is showing promise in improving the detection and management of idiopathic pulmonary fibrosis (IPF), ...

For the first time, people with bronchiectasis will have a treatment option. The U.S. Food and Drug Administration (FDA) has ...

In its second-quarter earnings release, the company said that in July and August 2025 it analyzed interim data from the ...

Consistently tracking KL-6 levels may help predict acute exacerbations in IPF and other types of fibrotic ILDs, a study ...

The FDA has approved Insmed’s brensocatib, the first treatment for non-cystic fibrosis bronchiectasis, a chronic and progressive lung disease affecting about 500,000 people in the U.S. The drug was ...

The U.S. Food and Drug Administration has approved Insmed's daily bronchiectasis pill, brensocatib, which will be sold under ...

In an increasingly challenging environment for scientific research funding, the American Lung Association Research Institute today announced the opening of its 2026-2027 Research Awards and Grants ...

Pune: Infantry soldier Tariq Aziz (30) is set to return to active duty after undergoing a bilateral lung transplant — the ...

Liquidia stock shot higher Tuesday after its new drug, Yutrepia, widely beat prescription and patient start expectations.

Large cohort study finds interstitial lung disease independently increases lung cancer risk across all major subtypes, even ...

YUTREPIA surpasses 900 unique patient prescriptions and 550 patient starts within 11 weeks after approval to treat PAH and PH-ILDPositive interim data from ASCENT trial reinforces YUTREPIA's tolerabil ...

The FDA has granted accelerated approval to Hernexeos for the treatment of adults with unresectable or metastatic non-squamous NSCLC.